Catalent
CTLT
Performance
About Catalent
Catalent is a leading global contract development and manufacturing organization (CDMO) that partners with pharma, biotech and self-care brands to accelerate the development, manufacturing, and delivery of therapies and consumer health products. The company provides end-to-end pharmaceutical solutions across multiple modalities, including biologics, cell and gene therapies, and oral and specialty dosage forms, with a worldwide network and advanced technologies. Its scope covers early-stage development through commercial manufacturing, supporting clients in bringing life-changing medicines and self-care products to market. Headquartered with a global presence, Catalent serves customers across regions worldwide.
Recent News
Catalent and Elpida Therapeutics Enter Strategic Partnership for Late-Phase AAV Manufacturing
Light-Controlled Gene Expression Platform Reportedly Doubles Standard Fed-Batch Manufacturing Performance
PCI Adds US Sterile Fill/Finish Capabilities Through $1B Global Expansion Drive
PDA Week 2026 Showcased AI, Knowledge Management, and Proactive Quality Culture
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
Smarter AAVs Drive Gene Therapy’s Next Chapter
Cartherics and Catalent Expand Commercial License Agreement
Greenhaven Road Capital Main Fund Q4 2025 Shareholder Letter
Selecting the Optimal Cell Therapy Manufacturing Platform
Recent Deals
No recent deals for this company.